期刊文献+

单克隆抗体A在液体制剂中铰链区裂解位点的鉴定

Identification of cleavage site in hinge region of monoclonal antibody A in liquid formulation
原文传递
导出
摘要 目的:对治疗性单克隆抗体A在液体制剂储存中发生裂解的位点进行鉴定。方法:单克隆抗体A在pH 5.9以及pH 6.5条件下,40℃保存1个月后,利用分子排阻色谱法(SEC)对产生的碎片进行分离收集,并用电喷雾-四级杆-飞行时间质谱进行分析,确定其裂解位点。结果:未经还原处理时,利用SEC法收集到的碎片相对分子质量为100 565.30,100 726.27和100 886.57 Da,经还原处理后,测得的相对分子质量为23500.80,26623.75,26785.96,26943.65,50448.09,50609.62和50766.90 Da。上述结果显示,发生裂解的位点为重链铰链区224位赖氨酸以及225位苏氨酸。结论:单克隆抗体A在溶液中发生裂解的位点是铰链区赖氨酸以及苏氨酸之间,该降解现象可通过降低贮存溶液的pH值得到控制。 Objective: To identify the cleavage site of therapeutic monoclonal antibody A( mAb A) during storage in liquid formulation. Methods: The mAb A was stored in liquid formulation with pH value of 5. 9 or 6. 5at 40 ℃ for 1 month. Fractions of fragmentation observed using size-exclusion chromatography( SEC) were collected and analyzed using electronic spray ionization quadrupole time of flight mass spectrometry( ESI-Q-TOF) to identify the cleavage site. Results: The observed molecular weights of the fragment collected using SEC-HPLC were100 565. 30 Da,100 726. 27 Da and 100 886. 57 Da without reduction,and 23 500. 80 Da,26 623. 75 Da,26 785. 96 Da,26 943. 65 Da,50 448. 09 Da,50 609. 62 Da and 50 766. 90 Da after reduction treatment. These results indicated that the cleavage site was between lysine 224 and threonine 225 on one heavy chain of mAb A in the hinge region. Conclusion: The cleavage site is lysine-threonine bond in the hinge region of mAb A when stored in liquid formulation,and the fragmentation could be controlled by lowering storage pH.
出处 《中国新药杂志》 CAS CSCD 北大核心 2014年第20期2442-2445,2449,共5页 Chinese Journal of New Drugs
关键词 单克隆抗体 铰链区 液质联用 液体制剂 PH值 monoclonal antibody hinge region LC-MS liquid formulation pH value
  • 相关文献

参考文献10

  • 1王志明,杨立霞,贾寅星,贺丞.基于新兴技术的单克隆抗体药物的研究进展[J].中国新药杂志,2012,21(18):2149-2155. 被引量:9
  • 2张天民.单克隆抗体药物的研究进展[J].医药导报,2005,24(6):494-498. 被引量:9
  • 3ELVIN JG,COURSTON RG,VAN DER WALLE CF. Therapeu- tic antibodies:Market considerations, disease targets and biopro- cessing [ J ]. Int J Pharm,2013,440 ( 1 ) : 83 - 98.
  • 4贾岩.“专利悬崖”前的单抗商机[N].医药经济报,2012-03-23(2).
  • 5CORDOBA AJ,SHYONG BJ,BREEN D,et al. Non-enzymatic hinge region fragmentation of antibodies in solution[J]. J Chrom- atogr B Analyt Technol Biomed Life Sci, 2005,818 (2) : 115 -121.
  • 6COHEN SL, PRICE C, VLASAK J. β-Elimination and peptide bond hydrolysis: two distinct mechanisms of human IgG1 hinge fragmentation upon storage [ J ]. J Am Chem Soc, 2007,129 ( 22 ) : 6976 - 6977.
  • 7YATES Z, GUNASEKARAN K, ZHOU H, et al. Histidine residue mediates radical-induced hinge cleavage of human IgG1 [ J]. J Biol Chem,2010,285(24) :18662 - 18671.
  • 8SMITH MA, EASTON M, EVERETT P,et al. Specific cleavage of immunoglobulin G by copper ions [ J]. lnt J Pept Protein Res, 1996,48(1) :48 -55.
  • 9KOLVENBACH CG, NARHI LO, PHILO JS,et al. Granulocyte- colony stimulating factor maintains a thermally stable, compact, partially folded structure at pH 2 [ J ]. J Pept Res, 1997,50 (4) : 310 -318.
  • 10MANNING MC, CHOU DK, MURPHY BM, et al. Stability of pro- tein pharmaeeuticals : an update [ J ]. Pharm Res, 2010,27 ( 4 ) : 544 - 575.

二级参考文献30

  • 1MUYLDERMANS S, BARAL T. N, RETAMOZZO V. C, et al. Camelid immunoglobulins and nanobody technology[ J]. Vet lm- munol lmmunopathol, 2009, 128( 1 -3) : 178 - 183.
  • 2WESOLOWSKI J, ALZOGARAY V, REYELT J, et al. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity [ J ]. Med Microbiol Immunol, 2009, 198(3) : 157 -174.
  • 3KOLKMAN JA, LAW DA. Nanobodies-from llamas to therapeu- tic proteins[J]. Drug Discov Today: Technol, 2010, 7 (2) : e139 - e146.
  • 4STIJLEMANS B, CALJON G, Natesan SKA, et al. High affinity nanobodies against the trypanosome brucei VSG are potenttrypanolytic agents that block endocytosis [ J]. PLoS Pathog, 2011,7 (6) : el002072.
  • 5HMILA I, SAERENS D, BEN ABDERRAZEK R,et al. A bispe- cific nanobody to provide full protection against lethal scorpion envenoming[ J]. FASEB J, 2010,24(9) :3479 - 3489.
  • 6KLOOSTER R, EMAN MR, LE DUC Q,et al. Selection and characterization of KDEL-specific VHH antibody fragments and their application in the study of ER resident protein expression [ J]. J lmmunol Methods,2009, 342 ( 1 - 2) : 1 - 12.
  • 7SERRUYS B, VAN HOUTTE F, FARHOUDI-MOGHADAM A, et al. Production, characterization and in vitro testing of HBcAg- specific VHH intrabodies [ J ]. J Gen Virol, 2010,91 ( Pt 3 ) : 643 - 652.
  • 8VAN DEN ABBEELE A, DE CLERCQ S, DE GANCK A, et al. A llamaderived gelsolin single-domain antibody blocks gelsolin-G- actin interaction[ J]. Cell Mol Life Sci, 2010,67(9) :1519 -1535.
  • 9VAN BOCKSTAELE F, HOLZ JB, REVETS H. The development of nanobodies for therapeutic applications [ J ]. urr Opin Investig Drugs,2009,10( 11 ) :1212 - 1224.
  • 10ULRICHTS H, SILENCE K, SCHOOLMEESTER A, et al. An- tithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs[J]. Blood, 2011,118(3) :757 -765.

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部